A Controlled Trial of Plasmapheresis in the Treatment of Renal Allograft Rejection

Kirubakaran, M.G.; Disney, A. P. S.; Norman, John; Pugsley, D. J.; Mathew, Timothy H.

doi:10.1097/00007890-198108000-00019

Cited by 62 publications

(37 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although performed in a very special and standardized immunologic context, which would appear to be a logical strategy for PE (i. e., presence of anti-donor Ab at the onset of the rejection episode), these observations, like other recent randomized [13] or nonrandomized studies [12], do not suggest a beneficial influence of PE in kidney rejection episodes, in contrast to the results of previous nonrandomized reports [14,15]. In addition, these data do not suggest that anti-donor Ab's play a major and direct role in graft destruction, but rather that they might only be testimony to a strong accompanying host immune response, as is also suggested by the appearance o f 'large' anti-panel antibodies and of autolymphocytotoxins.…”

Section: Discussionmentioning

confidence: 71%

Plasma Exchange in Early Kidney Graft Rejection Associated with Anti-Donor Antibodies

Jp¹,

Guyot²,

Guimbretière³

et al. 1983

Nephron

View full text Add to dashboard Cite

Patients with early rejection of kidney allografts associated with anti-donor antibodies have been randomized in two groups which received, respectively, either the conventional corticosteroid/azathioprine treatment or extensive plasma exchanges (PE) plus the conventional treatment. Data on the monitoring of anti-T or anti-B donor lymphocytes, as well as anti-panel or autoreactive cytotoxicity are described. Although the titer of anti-donor antibodies is decreased in the PE-treated group there is no sustained improvement of graft function compared to the control group. Thus, in these stereotyped rejection episodes, which are likely to be antibody mediated, there is no significant effect of extensive and early plasma exchange.

show abstract

Section: Discussionmentioning

confidence: 71%

Plasma Exchange in Early Kidney Graft Rejection Associated with Anti-Donor Antibodies

Jp¹,

Guyot²,

Guimbretière³

et al. 1983

Nephron

View full text Add to dashboard Cite

show abstract

“…However, a similar controlled study, recently reported by Kirubakaran and associates [6] failed to show any improvement in graft survival in the 12 patients receiving plasmapheresis along with standard immunosuppressive therapy. The major difference in apheresis protocols between the two investigators related to the amount of plasma volume removed.…”

Section: Cardella Et A1mentioning

confidence: 66%

Use of lymphoplasmapheresis or plasmapheresis in the management of acute renal allograft rejection

Kleinman

Nichols

Strauss

et al. 1982

J of Clinical Apheresis

View full text Add to dashboard Cite

Several recent reports have documented the value of intensive plasmapheresis as an adjunct to standard immunosuppressive therapy for patients suffering acute renal allograft rejection. We have treated four rejection episodes in three patients with intensive plasmapheresis and two rejection episodes in two additional patients with intensive lymphoplasmapheresis. Five of six rejection episodes were reversed, and four of the five patients treated have retained functioning grafts for follow-up periods ranging from 4 months to 3 years. Previous investigators have reported encouraging results using plasmapheresis, and we believe our experience supports the requirement for further controlled studies with this procedure. Moreover, we note that no previous work has been described with lymphoplasmapheresis and suggest that removal of lymphocytes, in addition to plasma, may further augment immunosuppression in the treatment of renal allograft rejection.

show abstract

“…Despite this recommendation, the evidence base for plasmapheresis is not consistently supportive (3,10,39,48). Plasmapheresis does not affect antibody synthesis and DSA levels rebound rapidly after plasmapheresis (2).…”

Section: Antibody Removalmentioning

confidence: 99%

Review of Bortezomib Treatment of Antibody-Mediated Rejection in Renal Transplantation

Ejaz

Alloway

Halleck

et al. 2014

Antioxidants & Redox Signaling

View full text Add to dashboard Cite

show abstract

A Controlled Trial of Plasmapheresis in the Treatment of Renal Allograft Rejection

Cited by 62 publications

References 0 publications

Plasma Exchange in Early Kidney Graft Rejection Associated with Anti-Donor Antibodies

Plasma Exchange in Early Kidney Graft Rejection Associated with Anti-Donor Antibodies

Use of lymphoplasmapheresis or plasmapheresis in the management of acute renal allograft rejection

Review of Bortezomib Treatment of Antibody-Mediated Rejection in Renal Transplantation

Contact Info

Product

Resources

About